Pentoxifylline synergizes with all-trans retinoic acid to induce differentiation of HL-60 myelocytic cells, but suppresses tRA-augmented clonal growth of normal CFU-GM

Acta Haematologica

Volumn 99, Issue 4, 1998, Pages 191-199

  Yang, K D ^a   Chao, C Y ^b   Shaio, M F ^b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Clonogenicity; Differentiation; Pentoxifylline; Retinoic acid syndrome

Indexed keywords

CD11B ANTIGEN; CELL ADHESION MOLECULE; CYCLIC AMP; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; RETINOIC ACID;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN HL 60; CLONOGENESIS; COLONY FORMING UNIT GM; CONTROLLED STUDY; GRANULOCYTE; GRANULOPOIESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MYELOID LEUKEMIA; PRIORITY JOURNAL; RESPIRATORY BURST;

ANTIGENS, CD11; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL DIVISION; CLONE CELLS; CYCLIC AMP; DRUG SYNERGISM; GRANULOCYTES; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MACROPHAGES; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RESPIRATORY BURST; TETRADECANOYLPHORBOL ACETATE; TRETINOIN;

EID: 0031972202     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040838     Document Type: Article

References (50)

1. Ruberte E, Dolle P, Chambon P, Morriss-Kay G: Retinoic acid receptors in the embryo. Development 1991;111:45-60.
2. Bryant SV, Gardiner DM: Retinoic acid, local cell-cell interactions, and pattern formation in vertebrate limbs. Dev Biol 1992;152:1-25.
3. Eccles S: Effects of retinoids on growth and dissemination of malignant tumors: Immunological considerations. Biochem Pharmacol 1985; 34:1599-1610.
4. Matikainen S, Serkkola E, Hurme M: Retinoic acid enhances IL-1b expression in myeloid leukemia cells and in human monocytes. J Immunol 1991;147:162-167.
5. Dillehay DL, Walia AS, Lamon EW: Effects of retinoids on macrophage function and IL-1 activity. J Leukoc Biol 1988;44:353-360.
6. Jones ME, Saleem A: Acute promyelocytic leukemia: A review of literature. Am J Med 1978; 65:673-677.
7. Huang ME, Ye YI, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY: Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-572.
8. Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boiviti P, Daniel MT, Berger R, Castaigne S, Degos L: Retinoic acid therapy for promyelocytic leukemia. Lancet 1989;ii: 746-747.
9. Abb J, Deihnardt F: Effects of retinoic acid on the human lymphocyte response to mitogens. Exp Cell Biol 1980;48:169-179.
10. Buck J, Dannecker L, Viswanathan K, Cohen SL, Chang BT, Hammerling U: Retinol is essential for growth of activated human B cells. J Exp Med 1990;171:1613-1624.
11. Lo Coco F, Avvisati G, Diverio D, Petti MC, Alcalay M, Pandolfi PP, Zangrilli D, Biondi A, Rambaldi A, Moleti ML, Mandelli F, Pelicci PG: Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. Blood 1991;77: 1657-1659.
12. 2) in acute promyelocytic leukemia. Blood 1993;82:3560-3563.
13. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell P Jr: The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-296.
14. Mahmoud HH, Hurwitz CA, Roberts WM, Santana VM, Ribeiro RC, Krance RA: Tretinoin toxicity in children with acute promyelocytic leukemia. Lancet 1993;342:1394-1395.
15. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR: Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience. Leukemia 1994;8(suppl):S33-37.
16. Seale J, Delva L, Renesto N, Dombret H, Scrobohaci M-L, Degos L, Paul P, Chomienne C: All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. Leukemia 1996;10:95-101.
17. Asami K, Sasazaki Y, Utsumi J: Successful treatment of retinoic acid syndrome with high dose dexamethasone pulse therapy in a child with acute promyelocytic leukemia treated with all-trans retinoic acid. Acta Paediatr Jpn 1995;37:384-387.
18. Mahendra P, Harman K, Phillips M, Gunning K, Marcus RE: Rapid progression of 'retinoic acid syndrome' in the hypogranular variant of acute promyelocytic leukemia despite treatment with dexamethasone and conventional chemotherapy. Clin Lab Haematol 1994;16: 371-374.
19. al-Bahar S, Pandita R, Hoffbrand AV: Bilateral osteonecrosis of the head of femur complicating acute promyelocytic leukemia: A sequel to treatment of retinoic acid treatment with dexamethasone. Acta Haematol 1996;96:88-91.
20. Dettelback HR, Aviado DM: Clinical pharmacology of pentoxifylline with special reference to its hemorheologic effect for the treatment of intermittent claudication. J Clin Pharmacol 1985;25:8-26.
21. Ward A, Clissold SP: Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
22. Welsh CH, Lien D, Wothen GS, Weil JV: Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. Am Rev Respir Dis 1988;138:1106-1114.
23. Yang KD, Stone RM, Wang LC, Wu NC, Shaio MF: Neuroblastoma cell-mediated leukocyte chemotaxis: lineage-specific differentiation of interleukin-8 expression. Exp Cell Res 1994; 211:1-5.
24. Yang KD, Chuon H-L, Shaio MF: Pentoxifylline augments but not antagonizes TNF-induced neuroblastoma cell differentiation: Modulation of free calcium mobilization but not cAMP. Biochem Biophys Res Commun 1995;211:1006-1014.
25. Yang KD, Datta R, Kharbanda SM, Huberman E, Kufe DW, Stone RM: All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia HL-60 cell line. Blood 1994;83:490-496.
26. Yang KD, Shaio MF: Hydroxyl radicals as an early signal involved in phorbol ester-induced monocytic differentiation of HL-60 cells. Biochem Biophys Res Commun 1994;200:1650-1657.
27. Yang KD, Stone RM, Lee CS, Chao TY, Cheng SN, Shaio MF: Effect of Picibanil (0K432) on neutrophil-mediated anti-tumor activity: Implication of monocyte-derived neutrophil activating factors. Cancer Immunol Immunother 1992;35:277-282.
28. Christensen RD, Harper TE, Rothstein G: Granulocyte-macrophage progenitor cells in term and preterm neonates. J Pediatr 1986; 109:1047-1051.
29. Yang KD, Shaio MF, Augustine NH, Hill HR: Effects of fibronectin on phagocyte activation: Implications in respiratory burst and actin polymerization. J Cell Physiol 1994;158:347-353.
30. Yang KD, Hill HR: Assessment of neutrophil function disorders: Practical and preventive interventions. Pediatr Infect Dis J 1994;13:906-919.
31. Rieneck K, Diamant M, Haahr PM, Schonharting M, Rendtzen K; In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 1993;37:131-138.
32. Kovach NL, Lindgren CF, Fefer A, Thompson JA, Yednock T, Harlan JM: Pentoxifylline inhibits integrin-mediated adherence of interleukin-2-activated human peripheral blood lymphocytes to human umbilical vein endothelial cells, matrix components, and cultured tumor cells. Blood 1994;84:2234-2242.
33. Hansen PR: In vitro studies on responses to pentoxifylline and aminophylline of rat mesenteric resistance vessels. Eur J Pharmacol 1994; 261:105-110.
34. Viladkar A, Chitnis M: In vitro effects of pentoxifylline and doxorubicin on cell survival and DNA damage in sensitive and MDR-P388 leukemia cells. Cancer Biother 1994;9:143-151.
35. Nakamalii T, Hino K, Yokoyama A, Hisatake J, Tomoyasu S, Honma Y, Hozumi M, Tsuruoka N: Effect of cytokines on the proliferation and differentiation of acute promyelocytic leukemia cells: Possible relationship to the development of retinoic acid syndrome. Anticancer Res 1994;14:817-823.
36. Dubois C, Schlageter MH, de Gentile A, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y, Degos L: Modulation of IL-8, IL-1b, and G-CSF secretion by all trans retinoic acid in acute promyelocytic leukemia. Leukemia 1994;8:1750-1757.
37. Nakajima H, Kizaki M, Sonoda A, Mori S, Harigaya K, Ideda Y: Retinoids (all-trans and 9-cis retinoic acid) stimulate production of macrophages colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by human bone marrow stromal cells. Blood 1994;84:4107-4115.
38. Prabhakar U, Lipshutz D, Truneh A: Inhibition of CD44, CD45 and LFA-3 mediated cytokine release from human monocytes by SK&F 86002 and pentoxifylline. Int J Immunopharmacol 1993;15:205-209.
39. Kovach NL, Lindgren CG, Fefer A, Thompson JA, Yednock T, Harlan JM: Pentoxifylline inhibits integrin-mediated adherence of interleukin-2 activated human peripheral blood lymphocytes to human umbilical vein endothelial cells, matrix components, and cultured tumor cells. Blood 1994;84:2234-2242.
40. Aronoff SC, Quinn FJ, Carpenter LS, Novick J: Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis. J Pediatr 1994;125:992-997.
41. Hubert DD, Holiat SM, Smith WE, Bayouny RA: Inhibition of transplanted carcinoma in mice by retinoids but not by vitamin C. Cancer Treat Rep 1983;67:1061-1065.
42. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-120.
43. Dion MW, Hussey DH, Doornbos JF, Vigliotti AP, Wen BC, Anderson B: Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Radiat Oncol Biol Phys 1990;19:401-407.
44. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shield A, Singer JW: Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991;78:1205-1211.
45. Dezube BJ, Fridovich-Keil JL, Bouvard I, Lange RF, Pardee AB: Oxpentifylline and well-being in patients with cancer. Lancet 1990;335: 662.
46. Sporn MB, Roberts AB: Role of retinoids in differentiation and carcinogenesis. Cancer Res 1983;43:3034-3040.
47. Olsson IL, Breitman TR, Gallo RC: Priming of human myeloid leukemic cell lines HL-60 and U-937 with retinoic acid for differentiation effects of cyclic adenosine 3′,5′-monophosphate-inducing agents and a T-lymphocyte-derived differentiation factor. Cancer Res 1982; 42:3928-3933.
48. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, Kunkel SL: Cellular and molecular regulation of tumor necrosis factor alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-1236.
49. Singer JW, Bianco JA, Takahashi G, Simrell C, Petersen J, Andrews DF III: Effect of methylxanthine derivatives on T cell activation. Bone Marrow Transplant 1992;10:19-25.
50. Rao KM, Crawford J, Currie MS, Cohen HJ: Actin depolymerization and inhibition of capping induced by pentoxifylline in human lymphocytes and neutrophils. J Cell Physiol 1988; 137:577-578.